While still fairly small, East Fork Cultivars has become one of the most respected cannabis cultivators in the Pacific Northwest.
Articles
Eleusis Looks For Alzheimer’s Breakthrough With Micro-Dosed LSD
Eleusis Therapeutics is a private psychedelics company that is turning a lot of heads with its research on micro-doses of LSD as a treatment for Alzheimer's.
Champignon Provides Corporate Update, Announces Name Change, Rebranding and Planned Spin Out
Champignon Brands is proposing changing its corporate name to Apotheosis Scientific Ltd, and announces a planned spin-off its consumer packaged goods (CPG) division.
Red Light Holland Engages Former Health Minister, the Honourable, Tony P. Clement, as Senior Advisor to Advisory Board
Former Canada Health Minister joins Red Light Holland as Senior Advisor.
MindMed And Eleusis Lead The Way In Psychedelics Micro-Dosing Research
Given that psychedelics micro-dosing has several commercial advantages, here are two companies that investors should look at.
Canadians More Receptive To Use Of Psilocybin For The Terminally Ill: New Poll
Canadians are rapidly warming up to the idea of using psilocybin to reduce distress among the terminally ill.
Mydecine Innovations Group Adds a Leading Neuroscientist and a Psychopharmacology Specialist
Mydecine's new Scientific Advisor will work directly with the CSO in new drug development initiatives.
What Does Field Trip Psychedelics Offer Investors?
Field Trip Psychedelics has just announced a letter of intent to go public via RTO.
ATAI launches IntroSpect Digital Therapeutics, Appoints veteran software engineer David Keene as CEO
ATAI is adding a digital therapeutics division to its R&D platform.
Mydecine Innovations Inks Important Research Agreement
Mydecine's research agreement with the University of Alberta is a key stepping-stone in expediting its psilocybin-based drug development research.
MindMed To Evaluate Ayahuasca's Active Ingredient DMT In A Phase 1 Clinical Trial Collaboration
MindMed is adding to its clinical trials on psychedelics with a Phase 1 collaboration aimed at ayahuasca research.
COMPASS Pathways Strengthens Leadership Team With Appointment of Trevor Mill as Chief Development Officer
Compass appoints a new Chief Development Officer as part of several new appointments to its management team.
Osoyoos Announces Agreement to Acquire AI Pharmaceuticals Jamaica Limited
Osoyoos cannabis has acquired a psilocybin-focuse biopharma company based in Jamaica.
GreenStar Biosciences Signs Agreement to Acquire 100% of Eleusian Biosciences Corp.
Greenstar Biosciences is entering the psychedelics space via its acquisition of Eleusian Biosciences Corp.
Mydecine Innovations Group Adds Former Pfizer, Novartis, Yale Drug Discovery Expert to Scientific Advisory Board
Mydecine's new Scientific Advisor will work directly with the CSO in drug development initiatives.